Definium LSD therapy shows anxiety relief in second late-stage trial
Definium Therapeutics announced Monday that its DT120 drug reduced anxiety scores significantly compared to placebo in a new twelve-week study.
Trial results show rapid effects
Patients receiving a 100-microgram dose of DT120 saw their Hamilton Anxiety Rating Scale scores drop by 9.8 points over the study period. The placebo group experienced a smaller reduction of 4.7 points during the same timeframe. Definium noted that some patients felt changes as early as the second day after taking the medication.
Comparison to existing treatments
The five-point difference between the drug and placebo matches results from the company's first late-stage anxiety study. This improvement is larger than what many other current anxiety therapies have observed historically. Traditional antidepressants typically require weeks to begin working, whereas this psychedelic treatment offers faster benefits.
Path toward regulatory approval
These findings position Definium to seek the first regulatory approval for a psychedelic drug specifically for anxiety. The company is part of an early wave of biotechnology firms nearing such clearance for these treatments. Rapid benefit appears especially attractive to patients seeking quicker relief from their symptoms.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.